Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: Suggestions for an improved dose regimen

British Journal of Clinical Pharmacology

Volumn 65, Issue 4, 2008, Pages 493-501

  Obua, Celestino ^a,b   Hellgren, Urban ^b   Ntale, Muhammed ^a   Gustafsson, Lars L ^b   Ogwal Okeng, Jasper W ^a   Gordi, Toufigh ^c   Jerling, Markus ^d  

^a MAKERERE UNIVERSITY   (Uganda)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY AT BUFFALO   (United States)

^d Markus Jerling Consulting AB   (Sweden)

Author keywords

Chloroquine; Falciparum malaria; Increased dose proposal; Population pharmacokinetics; Sulfadoxine

Indexed keywords

AMODIAQUINE; CHLOROQUINE; PYRIMETHAMINE; SULFADOXINE;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CAPILLARY FLOW; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE; TREATMENT FAILURE; UGANDA;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMALARIALS; CHILD, PRESCHOOL; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; SULFADOXINE; TREATMENT OUTCOME; UGANDA;

EID: 40549115018     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03050.x     Document Type: Article

References (23)

1. World Health Organization. Guidelines for the treatment of malaria. WHO/HTM/MAL/2006.1108. Geneva : WHO, 2006.
2. Ginsburg H. Should chloroquine be laid to rest? Acta Trop 2005 96 : 16 23.
3. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 2006 355 : 1959 66.
4. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther 2006 80 : 582 96.
5. Ministry of Health (MoH) Uganda. Implementation guidelines for the Home Based Management of Fever Strategy, 1st edn. Kampala : Ministry of Health, 2002.
6. Obua C, Ntale M, Lundblad MS, Mahindi M, Gustafsson LL, Ogwal-Okeng JW, Anokbonggo WW, Hellgren U. Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda. Afr Health Sci 2006 6 : 86 92.
7. Corvaisier S, Charpiat B, Mounier C, Wallon M, Leboucher G, Al Kurdi M, Chaulet JF, Peyron F. Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. Antimicrob Agents Chemother 2004 48 : 3794 80.
8. Trenque T, Simon N, Villena I, Chemla C, Quereux C, Leroux B, Jaussaud R, Remy G, Dupouy D, Millart H, Pinon JM, Urien S. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Br J Clin Pharmacol 2004 57 : 735 41.
9. World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. WHO/HTM/RBM/2003.50. Geneva : WHO, 2003.
10. Minzi OM, Rais M, Svensson JO, Gustafsson LL, Ericsson O. High-performance liquid chromatographic method for determination of amodiaquine, chloroquine and their monodesethyl metabolites in biological samples. J Chromatogr B Anal Technol Biomed Life Sci 2003 783 : 473 80.
11. Bergqvist Y, Hjelm E, Rombo L. Sulfadoxine assay using capillary blood samples dried on filter paper - suitable for monitoring of blood concentrations in the field. Ther Drug Monit 1987 9 : 203 7.
12. Jonsson EN, Karlsson MO. Xpose- an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999 58 : 51 64.
13. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982 8 : 195 222.
14. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics theory and clinical applications. Clin Pharmacokinet 1986 11 : 387 401.
15. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991 32 : 669 70.
16. Kauffman RE, Kearns GL. Pharmacokinetic studies in paediatric patients: clinical and ethical considerations. Clin Pharmacokinet 1992 23 : 10 29.
17. Obua C, Gustafsson LL, Aguttu C, Anokbonggo WW, Ogwal-Okeng JW, Chiria J, Hellgren U. Improved efficacy with amodiaquine instead of chloroquine in sulfadoxine/pyrimethamine combination treatment of falciparum malaria in Uganda: experience with fixed-dose formulation. Acta Trop 2006 100 : 142 50.
18. Walker O, Dawodu AH, Adeyokunnu AA, Salako LA, Alvan G. Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria. Br J Clin Pharmacol 1983 16 : 701 5.
19. Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, Hellstrom L, Jansson F. Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics. Clin Pharmacol Ther 1979 25 : 345 50.
20. Gustafsson LL, Walker O, Alvan G, Beermann B, Estevez F, Gleisner L, Lindstrom B, Sjoqvist F. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol 1983 15 : 471 9.
21. Adelusi SA, Dawodu AH, Salako LA. Kinetics of the uptake and elimination of chloroquine in children with malaria. Br J Clin Pharmacol 1982 14 : 483 7.
22. Weidekamm E, Plozza-Nottebrock H, Forgo I, Dubach UC. Plasma concentrations of pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerised curve fitting. Bull World Health Organ 1982 60 : 115 22.
23. Dzinjamala FK, Macheso A, Kublin JG, Taylor TE, Barnes KI, Molyneux ME, Plowe CV, Smith PJ. Association between pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrob Agents Chemother 2005 49 : 3601 6.